Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women - PubMed (original) (raw)
Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women
K Yaffe et al. Arch Neurol. 1997 Sep.
Abstract
Objective: To determine whether apolipoprotein E (Apo E) phenotype is associated with cognitive decline in community-dwelling nondemented elderly women.
Design: Prospective cohort study.
Setting: A university-affiliated clinic near Pittsburgh, Pa.
Patients: A total of 1750 nondemented community-dwelling women, aged 65 years and older, who were enrolled in the Study of Osteoporotic Fractures.
Main outcome measures: The women completed a baseline interview and performed 3 cognitive tests: the modified Mini-Mental State Examination, Trials B, and Digit Symbol. Serum samples were obtained for Apo E typing. Baseline cognitive scores and repeated scores approximately 6 years after study enrollment were compared in women with and without Apo E epsilon 4. Cognitive decline, defined as the worst 10th percentile change scores, was assessed for each test and by phenotype group.
Results: After adjustment for age, education, presence of severe tremor, and depression, baseline scores did not differ by Apo E epsilon 4 status except for lower scores on Trails B in the homozygous epsilon 4 group (mean score, 159.7 compared with 127.7 for the heterozygous epsilon 4 group and 125.4 for the no epsilon 4 group; P = .01). However, repeated test performance on follow-up examination was worse on all tests in those women with 1 or more epsilon 4. Reduction on the modified Mini-Mental State Examination was 0% for no epsilon 4 allele, 1.9% for 1 epsilon 4 allele, and 3.7% for 2 epsilon 4 alleles (P < .001); reduction on Digit Symbol was 6.2% for no epsilon 4 allele, 9.0% for 1 epsilon 4 allele, and 17.5% for 2 epsilon 4 alleles (P = .04); and reduction on Trials B was 5.9% for no epsilon 4 allele, 25.0% for 1 epsilon 4 allele, and 10.9% for 2 epsilon 4 alleles (P = .002). Women with at least 1 epsilon 4 had an odds ratio of 1.6 (95% confidence interval, 1.1-2.3) of having cognitive decline during the study period.
Conclusion: Apolipoprotein E epsilon 4 is associated with cognitive decline in community-dwelling nondemented women.
Similar articles
- Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women.
Yaffe K, Grady D, Pressman A, Cummings S. Yaffe K, et al. J Am Geriatr Soc. 1998 Jul;46(7):816-21. doi: 10.1111/j.1532-5415.1998.tb02713.x. J Am Geriatr Soc. 1998. PMID: 9670866 - Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group.
Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, Narayan KM, Cummings SR. Gregg EW, et al. Arch Intern Med. 2000 Jan 24;160(2):174-80. doi: 10.1001/archinte.160.2.174. Arch Intern Med. 2000. PMID: 10647755 - Depressive symptoms and cognitive decline in nondemented elderly women: a prospective study.
Yaffe K, Blackwell T, Gore R, Sands L, Reus V, Browner WS. Yaffe K, et al. Arch Gen Psychiatry. 1999 May;56(5):425-30. doi: 10.1001/archpsyc.56.5.425. Arch Gen Psychiatry. 1999. PMID: 10232297 - The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons.
Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. Haan MN, et al. JAMA. 1999 Jul 7;282(1):40-6. doi: 10.1001/jama.282.1.40. JAMA. 1999. PMID: 10404910 - Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population.
Brayne C, Harrington CR, Wischik CM, Huppert FA, Chi LY, Xuereb JH, O'Connor DW, Paykel ES. Brayne C, et al. Dementia. 1996 May-Jun;7(3):169-74. doi: 10.1159/000106873. Dementia. 1996. PMID: 8740632 Review.
Cited by
- Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use.
Jacobs EG, Kroenke C, Lin J, Epel ES, Kenna HA, Blackburn EH, Rasgon NL. Jacobs EG, et al. PLoS One. 2013;8(2):e54713. doi: 10.1371/journal.pone.0054713. Epub 2013 Feb 13. PLoS One. 2013. PMID: 23418430 Free PMC article. Clinical Trial. - Subjective cognitive concerns, episodic memory, and the APOE ε4 allele.
Samieri C, Proust-Lima C, M Glymour M, Okereke OI, Amariglio RE, Sperling RA, Rentz DM, Grodstein F. Samieri C, et al. Alzheimers Dement. 2014 Nov;10(6):752-759.e1. doi: 10.1016/j.jalz.2014.06.012. Epub 2014 Sep 23. Alzheimers Dement. 2014. PMID: 25256133 Free PMC article. - Characterization of vascular disease risk in postmenopausal women and its association with cognitive performance.
Dowling NM, Gleason CE, Manson JE, Hodis HN, Miller VM, Brinton EA, Neal-Perry G, Santoro MN, Cedars M, Lobo R, Merriam GR, Wharton W, Naftolin F, Taylor H, Harman SM, Asthana S. Dowling NM, et al. PLoS One. 2013 Jul 17;8(7):e68741. doi: 10.1371/journal.pone.0068741. Print 2013. PLoS One. 2013. PMID: 23874743 Free PMC article. - Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly.
Salmon DP, Ferris SH, Thomas RG, Sano M, Cummings JL, Sperling RA, Petersen RC, Aisen PS. Salmon DP, et al. Neuropsychology. 2013 Jul;27(4):391-401. doi: 10.1037/a0032707. Neuropsychology. 2013. PMID: 23876113 Free PMC article. - Cross-Sectional and Longitudinal Effects of CREB1 Genotypes on Individual Differences in Memory and Executive Function: Findings from the BLSA.
Wolf C, An Y, Tanaka T, Bilgel M, Gonzalez C, Kitner Triolo M, Resnick S. Wolf C, et al. Front Aging Neurosci. 2017 May 16;9:142. doi: 10.3389/fnagi.2017.00142. eCollection 2017. Front Aging Neurosci. 2017. PMID: 28559842 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical